Division of Digestive and Liver Diseases, Department of Medicine, Columbia University Medical Center, New York, New York.
Department of Pathology and Cell Biology, Columbia University Medical Center, New York, New York.
Gastroenterology. 2021 Feb;160(3):781-796. doi: 10.1053/j.gastro.2020.10.036. Epub 2020 Oct 29.
BACKGROUND & AIMS: Immune checkpoint inhibitors have limited efficacy in many tumors. We investigated mechanisms of tumor resistance to inhibitors of programmed cell death-1 (PDCD1, also called PD-1) in mice with gastric cancer, and the role of its ligand, PD-L1.
Gastrin-deficient mice were given N-methyl-N-nitrosourea (MNU) in drinking water along with Helicobacter felis to induce gastric tumor formation; we also performed studies with H/K-ATPase-hIL1B mice, which develop spontaneous gastric tumors at the antral-corpus junction and have parietal cells that constitutively secrete interleukin 1B. Mice were given injections of an antibody against PD-1 or an isotype control before tumors developed, or anti-PD-1 and 5-fluorouracil and oxaliplatin, or an antibody against lymphocyte antigen 6 complex locus G (also called Gr-1), which depletes myeloid-derived suppressor cells [MDSCs]), after tumors developed. We generated knock-in mice that express PD-L1 specifically in the gastric epithelium or myeloid lineage.
When given to gastrin-deficient mice before tumors grew, anti-PD-1 significantly reduced tumor size and increased tumor infiltration by T cells. However, anti-PD-1 alone did not have significant effects on established tumors in these mice. Neither early nor late anti-PD-1 administration reduced tumor growth in the presence of MDSCs in H/K-ATPase-hIL-1β mice. The combination of 5-fluorouracil and oxaliplatin reduced MDSCs, increased numbers of intra-tumor CD8 T cells, and increased the response of tumors to anti-PD-1; however, this resulted in increased tumor expression of PD-L1. Expression of PD-L1 by tumor or immune cells increased gastric tumorigenesis in mice given MNU. Mice with gastric epithelial cells that expressed PD-L1 did not develop spontaneous tumors, but they developed more and larger tumors after administration of MNU and H felis, with accumulation of MDSCs.
In mouse models of gastric cancer, 5-fluorouracil and oxaliplatin reduce numbers of MDSCs to increase the effects of anti-PD-1, which promotes tumor infiltration by CD8 T cells. However, these chemotherapeutic agents also induce expression of PD-L1 by tumor cells. Expression of PD-L1 by gastric epithelial cells increases tumorigenesis in response to MNU and H felis, and accumulation of MDSCs, which promote tumor progression. The timing and site of PD-L1 expression is therefore important in gastric tumorigenesis and should be considered in design of therapeutic regimens.
程序性细胞死亡蛋白 1(PDCD1,又称 PD-1)抑制剂在许多肿瘤中的疗效有限。我们研究了胃癌小鼠中肿瘤对 PD-1 抑制剂产生耐药的机制及其配体 PD-L1 的作用。
给予胃泌素缺陷型小鼠 MNU 饮用水和 H. felis 以诱导胃肿瘤形成;我们还进行了 H/K-ATPase-hIL1B 小鼠的研究,这些小鼠在胃窦-体交界处自发形成胃肿瘤,壁细胞持续分泌白细胞介素 1B。在肿瘤形成前,给小鼠注射抗 PD-1 抗体或同型对照抗体,或在肿瘤形成后,给小鼠注射抗 PD-1 加 5-氟尿嘧啶和奥沙利铂,或注射抗淋巴细胞抗原 6 复合物基因座 G(也称为 Gr-1)抗体,该抗体可耗尽髓样来源的抑制细胞(MDSCs)。我们生成了特异性在胃上皮细胞或髓系谱系中表达 PD-L1 的敲入小鼠。
在胃泌素缺陷型小鼠肿瘤生长前给予抗 PD-1 治疗,显著减小肿瘤大小并增加 T 细胞浸润肿瘤。然而,单独使用抗 PD-1 对这些小鼠的已建立肿瘤没有显著作用。在 H/K-ATPase-hIL-1β 小鼠中,无论是早期还是晚期给予抗 PD-1 治疗,都不能减少 MDSCs 的存在对肿瘤生长的影响。5-氟尿嘧啶和奥沙利铂的联合治疗减少了 MDSCs,增加了肿瘤内 CD8 T 细胞的数量,并增加了肿瘤对抗 PD-1 的反应;然而,这导致 PD-L1 在肿瘤中的表达增加。MNU 给药后,肿瘤或免疫细胞表达 PD-L1 增加了小鼠胃肿瘤的发生。表达 PD-L1 的胃上皮细胞未自发形成肿瘤,但在给予 MNU 和 H. felis 后,它们形成了更多更大的肿瘤,且 MDSCs 积累。
在胃癌的小鼠模型中,5-氟尿嘧啶和奥沙利铂减少 MDSCs 的数量,以增强抗 PD-1 的作用,促进 CD8 T 细胞浸润肿瘤。然而,这些化疗药物也诱导肿瘤细胞表达 PD-L1。胃上皮细胞表达 PD-L1 会增加对 MNU 和 H. felis 的反应,促进 MDSCs 的积累,从而促进肿瘤的进展。因此,PD-L1 的表达时间和部位在胃肿瘤发生中很重要,在设计治疗方案时应予以考虑。